{"filings":[{"id":1664797,"accession_number":"0001493152-26-033364","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-07-15T20:18:23+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.","Potential dilution: number of shares indeterminable; as of April 17, 2026, common shares outstanding ~402.9M; CEO David Koos is a creditor and will be paid after one year.","Created Series N Preferred Stock: 1,000 shares authorized, each with 75 million votes, enabling concentrated voting control.","Changed auditor: BCRG replaced by Simon & Edward LLP after acquisition; no disagreements, but prior reports had going concern qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105896,"accession_number":"0001493152-26-008837","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.","Shares were issued in unregistered private placement under Section 4(a)(2) with no underwriter or commission.","Post-issuance outstanding shares total 212,318,424 as of March 3, 2026.","Implied issuance price of approximately $0.0009 per share, suggesting severe dilution for existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105895,"accession_number":"0001493152-26-004733","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.","On Jan 29, 2026, issued 5,302,732 shares to satisfy $12,000 principal + $1,000 interest.","On Jan 30, 2026, issued 11,111,111 shares for $50,000 cash via Reg A offering.","As of Feb 2, 2026, total shares outstanding: 129,468,577; implied average issuance price ~$0.003 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105894,"accession_number":"0001493152-26-002956","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma declares 1:1 dividend of Series A Preferred stock for all share classes","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared dividend of one share of Series A Preferred for each share of Common, Series A, AA, M, and NC Preferred owned.","Record date is February 3, 2026; payable on or about February 9, 2026.","Dividend payable in authorized but unissued Series A Preferred stock.","All shareholders of record as of Record Date will receive the dividend on a 1:1 basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122157,"accession_number":"0001493152-25-022185","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":[],"status":"ready","headline":"Regen BioPharma issues 23.68M common shares for cash and debt conversion in Oct-Nov 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Oct 8, 2025: issued 6.8M shares for $68,000 cash.","Oct 27, 2025: issued 3.5M shares for $35,000 cash, and 4.5M shares to satisfy $30,204 debt principal plus $13,536 accrued interest.","Oct 28, 2025: issued 7.1M shares for $71,000 cash.","Nov 10, 2025: issued 1.78M shares for $17,800 cash under Tier 2 Reg A offering.","All shares sold directly by management with no underwriter or commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122156,"accession_number":"0001493152-25-016767","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.","Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.","Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.","Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.","Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138885,"accession_number":"0001493152-25-014182","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":[],"status":"ready","headline":"Regen Biopharma raises $58.2K via unregistered sales of 5.82M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sep 15, 2025, issued 3,320,000 shares for $33,200 to an unaffiliated investor.","On Sep 16, 2025, issued 1,000,000 shares for $10,000 to an unaffiliated investor.","On Sep 18, 2025, issued 1,500,000 shares for $15,000 to an unaffiliated investor.","All proceeds will be used for working capital; shares sold in private placements without registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138884,"accession_number":"0001641172-25-022575","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.","6% interest per annum; maturity date August 5, 2026.","Conversion price is 60% of lowest trading price over prior 20 trading days.","Beneficial ownership limitation set at 4.99% (can be increased to 9.99% by holder).","Shares upon conversion are unregistered and subject to restrictive legend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138883,"accession_number":"0001641172-25-021882","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma enters $130K convertible note financing with CFI Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.","Note matures July 28, 2026; interest payable in common stock at holder's option.","Conversion price set at 60% of lowest trading price over prior 20 trading days on OTC Markets.","Company reserved 15,700,485 common shares for conversion; holder must maintain 5x coverage reserve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156364,"accession_number":"0001641172-25-014652","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.","Shares issued under Section 4(a)(2) exempt offering; no underwriters or commissions paid.","Settlement agreement (Ex-10.1) reveals total unpaid salary of $457,113.19; only $50K settled with shares.","Post-issuance, shares outstanding increased to 31,554,704 from ~21.6M, a ~46% dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156363,"accession_number":"0001641172-25-009967","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Regen Biopharma restates FY2024 financials; prior statements not reliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.","Derivative liability increased by $6,816; total liabilities restated to $5.38M.","Net loss restated from $809,255 to $668,255, improvement of $198,995.","Prepaid assets reduced by $16,527; total assets restated to $161,084.","Additional paid-in capital decreased by $17,492; AOCI shows negative $204,847 from reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156362,"accession_number":"0001641172-25-002908","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.","Engaged BCRG Group as new independent registered public accounting firm same date.","No disagreements with Bush on accounting principles or practices during engagement.","Bush only completed interim review for period ended June 30, 2024; no audit conducted.","Company requested Bush to furnish letter to SEC; no response received as of April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191747,"accession_number":"0001493152-24-048090","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.","Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.","Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.","Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.","Company remains development-stage; no FDA approvals for any product candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":236560.0,"consensus_period":"2024-09-30","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208221,"accession_number":"0001493152-24-037011","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma declares 1-for-1 stock dividend payable Nov 1","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of one common share for each share of common and Series A, AA, M, NC preferred stock held.","Record date is October 17, 2024; payment on or about November 1, 2024.","Shares will come from authorized but unissued common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208220,"accession_number":"0001493152-24-036161","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $250K; original issue discount $25K, net proceeds $200K.","10% annual interest; ten monthly payments of $27,500 starting Nov 4, 2024, due Sept 4, 2025.","Upon event of default, note converts to common stock at 90% of lowest 20-day trading price before conversion.","Company issued 500K commitment shares; 350K to be returned to treasury if no default occurs.","$152K of proceeds used to repay existing principal and interest to Coventry from a prior note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225808,"accession_number":"0001607062-24-000219","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma appoints Bush and Associates CPA as new independent auditor effective May 28, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved engagement of Bush and Associates CPA LLC as independent auditor on May 28, 2024.","Filing does not disclose previous auditor or reasons for change.","Effective date of engagement is May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225807,"accession_number":"0001607062-24-000211","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Regen Biopharma declares Series A Preferred stock dividend and amends charter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 20, 2024, amended Certificate of Incorporation to allow share dividends between classes/series.","Board declared a dividend of 2 shares of Series A Preferred for each share of Common, Series A, AA, M, NC Preferred owned.","Record date: June 20, 2024; payment date: on or about July 1, 2024.","No ticker provided; company is an emerging growth company with no securities registered under Section 12(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225806,"accession_number":"0001607062-24-000175","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.","SEC order instituted administrative and cease-and-desist proceedings against BF Borgers and its sole partner.","No disagreements or reportable events occurred with BF Borgers during fiscal years 2022 and 2023.","Company will need to engage a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225805,"accession_number":"0001607062-24-000150","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.","Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.","Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.","Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.","Both transactions involve related party: David Koos is CEO and also controls BST Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244928,"accession_number":"0001607062-24-000053","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filed a provisional patent application with the USPTO on February 7, 2024.","Covers compositions, protocols, and treatment means for accelerating hematopoietic reconstitution.","Targets recovery after insult or chronic pathology using stem cell-derived endothelial progenitor or endothelial cells.","Application protects a potential regenerative medicine therapy for bone marrow or blood cell restoration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279576,"accession_number":"0001607062-23-000434","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Regen Biopharma enters $175K promissory note and $10M equity line with Coventry","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds $148,750 after $26,250 original issue discount; note matures March 2025.","Note carries 10% interest, convertible upon default at 90% of lowest 20-day trading price.","Equity line allows draw downs at 80% of lowest price over prior 10 business days; max $250K per draw.","Coventry receives 125,000 commitment shares; registration statement to cover up to 1,126,954 shares.","Draw downs limited to 200% of average daily dollar traded value; beneficial ownership cap 4.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318221,"accession_number":"0001607062-23-000142","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["3.02","3.03"],"status":"ready","headline":"Regen Biopharma issues 15K Series NC preferred shares to CEO with super-voting rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 15,000 Series NC preferred shares to CEO David Koos to settle $10,050 debt.","Each Series NC share carries 334 votes, disproportionately high voting power.","Issuance dilutes common stock voting power and has anti-takeover effect.","Board authorized 20,000 shares of Series NC; 15,000 issued now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318220,"accession_number":"0001607062-23-000078","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Regen Biopharma files 1-for-1500 reverse stock split and reduces preferred voting power","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series AA preferred votes reduced to 7 per share; Series NC to 334 per share, effective March 6, 2023.","1-for-1500 reverse stock split authorized for all common and preferred stock, effective March 6, 2023.","Reverse split consolidates shares at a 1500:1 ratio, drastically reducing outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336496,"accession_number":"0001607062-22-000724","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 55.8M Series A Preferred shares to settle $376,711 in convertible debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 55,809,233 Series A Preferred shares to satisfy $250,000 principal and $126,711 accrued interest on convertible promissory notes.","Shares issued directly by management under Section 4(a)(2) exemption; no underwriters or commissions paid.","As of Nov 21, 2022, $510,000 of convertible notes outstanding, including $360,000 convertible at floating rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336495,"accession_number":"0001607062-22-000714","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 101.9M Series A Preferred and 16.9M common shares in debt-for-equity swap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 101,880,008 shares of Series A Preferred to satisfy $511,500 convertible debt and $253,816 accrued interest.","Issued 16,912,946 common shares to satisfy $25,369 accrued interest on a convertible note.","Total debt and interest converted: $790,685 ($511,500 principal + $279,185 interest).","Securities issued under Section 4(a)(2) private placement exemption; no underwriters or commissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336494,"accession_number":"0001607062-22-000669","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["5.03","8.01"],"status":"ready","headline":"Regen Biopharma increases authorized Series A Preferred shares to 739M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series A Preferred Stock authorized shares increased to 739,000,000 via amendment to Certificate of Designation.","Amendment to Section 1 of the Certificate of Designation effective November 3, 2022.","Company presented at Emerging Growth Conference on November 9, 2022; video available via YouTube link."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353901,"accession_number":"0001607062-22-000586","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.","Company claims it is the first combination of immunotherapy and gene silencing in a single drug.","Technology uses aptamers (short DNA/RNA) to deliver gene-silencing sequences while inhibiting traditional immune checkpoints like PD-1.","CEO David Koos believes platform will yield numerous potent therapeutic candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353900,"accession_number":"0001607062-22-000495","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.","Patent covers methods, means and compositions for enhancing antitumor activity of CAR T cells through dedifferentiation.","CAR T cells are modified immune T cells that attack cancer-specific antigens; developed from bone marrow stem cells.","Provisional application marks initial step in securing IP for this cancer treatment approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353899,"accession_number":"0001607062-22-000464","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 54.5M shares to retire $180,552 convertible note with Coventry","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 54,514,492 common shares to Coventry Enterprises LLC to satisfy $180,552 of convertible indebtedness.","Principal and accrued interest on $1.5M promissory note now $0 as of July 19, 2022.","Shares issued under Section 4(a)(2) exemption; no underwriter or commission paid.","Significant dilution for existing shareholders; all outstanding convertible debt now retired."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371748,"accession_number":"0001607062-22-000359","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.","KCL Therapeutics subsidiary awarded U.S. Patent No. 11,324,719 for small molecule NR2F6 agonists/antagonists.","Shares issued under Section 4(a)(2) exemption without underwriters or general solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390689,"accession_number":"0001607062-22-000196","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Regen Biopharma increases authorized common shares to 5.8B; amends preferred share classes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 4.8B to 5.8B, par value $0.0001.","Series A Preferred authorized set at 540M shares; Series M Preferred at 60M shares.","Total authorized capital includes 5.8B common, 540M Series A preferred, 60M Series M preferred.","Amendment effective March 17, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390688,"accession_number":"0001607062-22-000137","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma terminates acquisition negotiations for Canary Oncoceutics stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated all negotiations to acquire 95% of Canary Oncoceutics.","LOI signed Nov 11, 2021, consideration: $1M cash + stock valued at pre-closing avg price.","As of Feb 18, 2022, no definitive agreement reached; negotiations ended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390687,"accession_number":"0001607062-22-000013","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Regen Biopharma subleases office space from BST Partners controlled by CEO David Koos at $5,000/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into month-to-month sublease with BST Partners for office space at 4700 Spring Street, Suite 304, La Mesa, CA starting January 14, 2022.","Monthly rent of $5,000 payable to BST Partners, which is controlled by David Koos, Regen's sole officer and director.","Sublease creates a direct financial obligation and is a related-party transaction due to Koos's control of both entities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408760,"accession_number":"0001607062-21-000639","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Regen Biopharma restates June 30, 2021 financials; $1.9M revenue incorrectly recognized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concluded Q2 and nine-month FY2021 financials should no longer be relied upon.","$1,905,000 of license revenue recognized upfront should be amortized over 15 years.","Restatement reduces Q2 revenue from $1.9M to $29,206; net loss increases by $1,875,794.","Unearned income of $1,875,794 added to liabilities; total liabilities now $13.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408759,"accession_number":"0001607062-21-000626","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-12-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma pays down $1.02M of convertible notes, principal now $1.34M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal indebtedness on convertible notes reduced from $2,364,075 (Jun 30) to $1,340,621 (Dec 13, 2021).","Company satisfied $1,023,454 of principal debt between July 1 and Dec 13, 2021.","This represents a 43% reduction in principal debt over approximately 5.5 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408758,"accession_number":"0001607062-21-000512","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.","Closing contingent on raising $50,000,000 solely for Canary diagnostics and product development.","Milestone payments up to $10,000,000 per test product, including $3M upon FDA approval.","Earned royalty on net sales: 2.5% up to $250M, 4% up to $500M, 5% above $500M.","IP licensed from Cornell University enables patient-derived tumor vascular nets for drug testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408757,"accession_number":"0001607062-21-000487","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-11-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma reduces convertible note principal by $967,830 via equity and cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.","Outstanding convertible note principal fell from $2.36M (June 30, 2021) to $1.40M (November 4, 2021).","Total debt reduction of approximately $1.51M includes principal, fees, penalties, and accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408756,"accession_number":"0001607062-21-000481","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.","Invention targets NR2F6 silencing or gene editing in cord blood cells to produce potentiated killer cells for anticancer therapy.","Patent includes compositions of matter, cells, and treatment protocols for inducing anticancer immune responses.","Allogeneic cord blood killer cells are administered to initiate antitumor immune responses, first allogeneic then endogenous."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408755,"accession_number":"0001607062-21-000444","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen BioPharma settles convertible notes for $43,529 cash to avoid potential issuance of 855M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settled convertible notes principal of $29,836 and accrued interest of $26,227 for $43,529.30 cash.","Notes had a default conversion provision allowing conversion at 65% of lowest bid price during delinquency.","Company determined provision could permit conversion even after cure, enabling up to 855,584,615 shares worth $16.6M.","Settlement eliminates the default-conversion risk and potential massive dilution for existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408754,"accession_number":"0001607062-21-000431","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.","Total fee of $25,000 due immediately upon SOW signing; work to be completed by November 15, 2021.","Deliverables include a gap assessment report and a regulatory strategy work package for NR2F6 IP.","Scope of Work Order effective October 11, 2021, under existing Master Services Agreement dated May 12, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427686,"accession_number":"0001607062-21-000355","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.","Invention relates to compounds that alter NR2F6 activity, a nuclear receptor involved in immune regulation.","Allowed patent strengthens Regen's IP position for its small molecule immunomodulator program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427685,"accession_number":"0001607062-21-000349","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-09-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.","Note carries 5% guaranteed interest, matures July 2022, convertible only upon default.","Paid $800K to ChemDiv to settle lawsuit; settlement includes release of claims and protects IP.","CEO David Koos reports progress: current SEC filings, $1.905M licensing revenue in Q2 2021, revived patents.","Goals include settling all convertible notes, hiring CSO, and seeking OTCQB listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427684,"accession_number":"0001607062-21-000331","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Regen Biopharma settles ChemDiv lawsuit for $800k, contingent on SEC filing by Sept 24","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Regen to pay $800k lump sum by Sept 30, 2021, to settle ChemDiv's breach-of-contract lawsuit over ~$1.2M unpaid invoices.","Settlement contingent on Regen filing acceptable SEC documents by Sept 24 to maintain listing status.","Upon payment, ChemDiv dismisses litigation with prejudice and transfers NR2F6 research data, compounds, and IP to Regen and Zander.","If payment not made by Sept 30, agreement void and litigation continues with trial set for Oct 29, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427683,"accession_number":"0001607062-21-000307","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-08-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma files Q2 2021 10-Q, ends reporting delinquency; plans convertible debt settlement to curb dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed quarterly report for period ended June 30, 2021; now current on SEC filings.","No convertible debt issued since July 2020; no plans to issue additional convertible instruments.","Intends to negotiate settlement of remaining convertible notes to eliminate or limit dilution; no assurances of favorable terms or execution.","Remaining noteholders may not agree to terms, and any settlement may not be on terms favorable to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427678,"accession_number":"0001607062-21-000309","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K/A","filed_at":"2021-08-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma corrects convertible debt date, becomes current on SEC filings, plans to settle notes","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Corrects earlier statement: no convertible debt issued since July 2019, not July 2020.","Company is no longer delinquent in SEC reporting as of August 27, 2021 10-Q filing.","Intends to negotiate settlement of remaining convertible notes to reduce or eliminate dilution, no assurance given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427682,"accession_number":"0001607062-21-000297","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-08-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for \"Antigen Specific MRNA Cellular Cancer Vaccines\".","The invention covers modified mRNA encoding immunogenic epitopes, e.g., survivin-derived peptides, to induce intracellular antigen production.","Patent aims to expand epitope repertoire presented to adaptive immune system, improving likelihood of successful immunity induction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427681,"accession_number":"0001607062-21-000214","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-07-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma begins audit of FY2020 financials to cure reporting delinquency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BF Borgers CPA PC started audit of FY2020 financial statements on July 8, 2021.","Audit is a step towards filing overdue Form 10-K for fiscal year ended September 30, 2020.","Borgers also audited FY2019 and FY2018 statements for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427680,"accession_number":"0001607062-21-000210","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).","Notice of allowance received for antigen-specific mRNA cancer vaccine (app. 15/162,370).","Two patent assets in revival: siRNA cancer therapy (8,389,708) and universal donor cord blood killer cells (15/494,358).","Active applications include NR2F6 inhibition combined with cannabidiol for cancer, angiogenesis, arthritis; small molecule NR2F6 modulators.","Zander Therapeutics licensed patent for canine dendritic cell immunotherapy (10,030,227)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427679,"accession_number":"0001607062-21-000187","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2021-07-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.","Invention pertains to generating IL-17 antitumor effector cells by inhibiting NR2F6.","NR2F6 described as an immune checkpoint and cancer stem cell differentiator."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}